COVID-19 Impact on Global HER-2 Targeted Drugs for Breast Cancer Market Size, Status and Forecast 2020-2026
![](/report_cover/6975/covid-19-impact-on-global-her-2-targeted-drugs-4-breast-cancer-market-size-status-n-forecast-2020-2026_en.gif)
This report focuses on the global HER-2 Targeted Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the HER-2 Targeted Drugs for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Roche
- Chugai Pharmaceutical
- GlaxoSmithKline
- Novartis
- Pfizer
- CANbridge
- Puma Biotechnology
- Hengrui Medicine
- Beacon Pharmaceuticals Limited
- Hetero Drugs
- Trastuzumab
- Pertuzumab
- Lapatinib
- Neratinib
- Trastuzumab Emtansine
- Pyrotinib
- Other
- Hospital
- Clinic
- Drug Center
- Other
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global HER-2 Targeted Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players.
- To present the HER-2 Targeted Drugs for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by HER-2 Targeted Drugs for Breast Cancer Revenue
1.4 Market Analysis by Type
1.4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Trastuzumab
1.4.3 Pertuzumab
1.4.4 Lapatinib
1.4.5 Neratinib
1.4.6 Trastuzumab Emtansine
1.4.7 Pyrotinib
1.4.8 Other
1.5 Market by Application
1.5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Drug Center
1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): HER-2 Targeted Drugs for Breast Cancer Industry Impact
1.6.1 How the Covid-19 is Affecting the HER-2 Targeted Drugs for Breast Cancer Industry
1.6.1.1 HER-2 Targeted Drugs for Breast Cancer Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and HER-2 Targeted Drugs for Breast Cancer Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for HER-2 Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 HER-2 Targeted Drugs for Breast Cancer Market Perspective (2015-2026)
2.2 HER-2 Targeted Drugs for Breast Cancer Growth Trends by Regions
2.2.1 HER-2 Targeted Drugs for Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 HER-2 Targeted Drugs for Breast Cancer Historic Market Share by Regions (2015-2020)
2.2.3 HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 HER-2 Targeted Drugs for Breast Cancer Market Growth Strategy
2.3.6 Primary Interviews with Key HER-2 Targeted Drugs for Breast Cancer Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Market Size
3.1.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Revenue (2015-2020)
3.1.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Players (2015-2020)
3.1.3 Global HER-2 Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio
3.2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by HER-2 Targeted Drugs for Breast Cancer Revenue in 2019
3.3 HER-2 Targeted Drugs for Breast Cancer Key Players Head office and Area Served
3.4 Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service
3.5 Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Type (2015-2020)
4.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2021-2026)
5 HER-2 TARGETED DRUGS FOR BREAST CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
5.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
6.2 HER-2 Targeted Drugs for Breast Cancer Key Players in North America (2019-2020)
6.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
6.4 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
7.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Europe (2019-2020)
7.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
7.4 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
8 CHINA
8.1 China HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
8.2 HER-2 Targeted Drugs for Breast Cancer Key Players in China (2019-2020)
8.3 China HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
8.4 China HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
9.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Japan (2019-2020)
9.3 Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
9.4 Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
10.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
11 INDIA
11.1 India HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
11.2 HER-2 Targeted Drugs for Breast Cancer Key Players in India (2019-2020)
11.3 India HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
11.4 India HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
12.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
12.4 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Roche
13.1.1 Roche Company Details
13.1.2 Roche Business Overview and Its Total Revenue
13.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Introduction
13.1.4 Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020))
13.1.5 Roche Recent Development
13.2 Chugai Pharmaceutical
13.2.1 Chugai Pharmaceutical Company Details
13.2.2 Chugai Pharmaceutical Business Overview and Its Total Revenue
13.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Introduction
13.2.4 Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.2.5 Chugai Pharmaceutical Recent Development
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Details
13.3.2 GlaxoSmithKline Business Overview and Its Total Revenue
13.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Introduction
13.3.4 GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.3.5 GlaxoSmithKline Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview and Its Total Revenue
13.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Introduction
13.4.4 Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 Pfizer
13.5.1 Pfizer Company Details
13.5.2 Pfizer Business Overview and Its Total Revenue
13.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Introduction
13.5.4 Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.5.5 Pfizer Recent Development
13.6 CANbridge
13.6.1 CANbridge Company Details
13.6.2 CANbridge Business Overview and Its Total Revenue
13.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Introduction
13.6.4 CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.6.5 CANbridge Recent Development
13.7 Puma Biotechnology
13.7.1 Puma Biotechnology Company Details
13.7.2 Puma Biotechnology Business Overview and Its Total Revenue
13.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Introduction
13.7.4 Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.7.5 Puma Biotechnology Recent Development
13.8 Hengrui Medicine
13.8.1 Hengrui Medicine Company Details
13.8.2 Hengrui Medicine Business Overview and Its Total Revenue
13.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Introduction
13.8.4 Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.8.5 Hengrui Medicine Recent Development
13.9 Beacon Pharmaceuticals Limited
13.9.1 Beacon Pharmaceuticals Limited Company Details
13.9.2 Beacon Pharmaceuticals Limited Business Overview and Its Total Revenue
13.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Introduction
13.9.4 Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.9.5 Beacon Pharmaceuticals Limited Recent Development
13.10 Hetero Drugs
13.10.1 Hetero Drugs Company Details
13.10.2 Hetero Drugs Business Overview and Its Total Revenue
13.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Introduction
13.10.4 Hetero Drugs Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.10.5 Hetero Drugs Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by HER-2 Targeted Drugs for Breast Cancer Revenue
1.4 Market Analysis by Type
1.4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Trastuzumab
1.4.3 Pertuzumab
1.4.4 Lapatinib
1.4.5 Neratinib
1.4.6 Trastuzumab Emtansine
1.4.7 Pyrotinib
1.4.8 Other
1.5 Market by Application
1.5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Drug Center
1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): HER-2 Targeted Drugs for Breast Cancer Industry Impact
1.6.1 How the Covid-19 is Affecting the HER-2 Targeted Drugs for Breast Cancer Industry
1.6.1.1 HER-2 Targeted Drugs for Breast Cancer Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and HER-2 Targeted Drugs for Breast Cancer Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for HER-2 Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 HER-2 Targeted Drugs for Breast Cancer Market Perspective (2015-2026)
2.2 HER-2 Targeted Drugs for Breast Cancer Growth Trends by Regions
2.2.1 HER-2 Targeted Drugs for Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 HER-2 Targeted Drugs for Breast Cancer Historic Market Share by Regions (2015-2020)
2.2.3 HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 HER-2 Targeted Drugs for Breast Cancer Market Growth Strategy
2.3.6 Primary Interviews with Key HER-2 Targeted Drugs for Breast Cancer Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Market Size
3.1.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Revenue (2015-2020)
3.1.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Players (2015-2020)
3.1.3 Global HER-2 Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio
3.2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by HER-2 Targeted Drugs for Breast Cancer Revenue in 2019
3.3 HER-2 Targeted Drugs for Breast Cancer Key Players Head office and Area Served
3.4 Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service
3.5 Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Type (2015-2020)
4.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2021-2026)
5 HER-2 TARGETED DRUGS FOR BREAST CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
5.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
6.2 HER-2 Targeted Drugs for Breast Cancer Key Players in North America (2019-2020)
6.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
6.4 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
7.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Europe (2019-2020)
7.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
7.4 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
8 CHINA
8.1 China HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
8.2 HER-2 Targeted Drugs for Breast Cancer Key Players in China (2019-2020)
8.3 China HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
8.4 China HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
9.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Japan (2019-2020)
9.3 Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
9.4 Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
10.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
11 INDIA
11.1 India HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
11.2 HER-2 Targeted Drugs for Breast Cancer Key Players in India (2019-2020)
11.3 India HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
11.4 India HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
12.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
12.4 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Roche
13.1.1 Roche Company Details
13.1.2 Roche Business Overview and Its Total Revenue
13.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Introduction
13.1.4 Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020))
13.1.5 Roche Recent Development
13.2 Chugai Pharmaceutical
13.2.1 Chugai Pharmaceutical Company Details
13.2.2 Chugai Pharmaceutical Business Overview and Its Total Revenue
13.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Introduction
13.2.4 Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.2.5 Chugai Pharmaceutical Recent Development
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Details
13.3.2 GlaxoSmithKline Business Overview and Its Total Revenue
13.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Introduction
13.3.4 GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.3.5 GlaxoSmithKline Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview and Its Total Revenue
13.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Introduction
13.4.4 Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 Pfizer
13.5.1 Pfizer Company Details
13.5.2 Pfizer Business Overview and Its Total Revenue
13.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Introduction
13.5.4 Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.5.5 Pfizer Recent Development
13.6 CANbridge
13.6.1 CANbridge Company Details
13.6.2 CANbridge Business Overview and Its Total Revenue
13.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Introduction
13.6.4 CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.6.5 CANbridge Recent Development
13.7 Puma Biotechnology
13.7.1 Puma Biotechnology Company Details
13.7.2 Puma Biotechnology Business Overview and Its Total Revenue
13.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Introduction
13.7.4 Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.7.5 Puma Biotechnology Recent Development
13.8 Hengrui Medicine
13.8.1 Hengrui Medicine Company Details
13.8.2 Hengrui Medicine Business Overview and Its Total Revenue
13.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Introduction
13.8.4 Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.8.5 Hengrui Medicine Recent Development
13.9 Beacon Pharmaceuticals Limited
13.9.1 Beacon Pharmaceuticals Limited Company Details
13.9.2 Beacon Pharmaceuticals Limited Business Overview and Its Total Revenue
13.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Introduction
13.9.4 Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.9.5 Beacon Pharmaceuticals Limited Recent Development
13.10 Hetero Drugs
13.10.1 Hetero Drugs Company Details
13.10.2 Hetero Drugs Business Overview and Its Total Revenue
13.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Introduction
13.10.4 Hetero Drugs Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
13.10.5 Hetero Drugs Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. HER-2 Targeted Drugs for Breast Cancer Key Market Segments
Table 2. Key Players Covered: Ranking by HER-2 Targeted Drugs for Breast Cancer Revenue
Table 3. Ranking of Global Top HER-2 Targeted Drugs for Breast Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Trastuzumab
Table 6. Key Players of Pertuzumab
Table 7. Key Players of Lapatinib
Table 8. Key Players of Neratinib
Table 9. Key Players of Trastuzumab Emtansine
Table 10. Key Players of Pyrotinib
Table 11. Key Players of Other
Table 12. COVID-19 Impact Global Market: (Four HER-2 Targeted Drugs for Breast Cancer Market Size Forecast Scenarios)
Table 13. Opportunities and Trends for HER-2 Targeted Drugs for Breast Cancer Players in the COVID-19 Landscape
Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 15. Key Regions/Countries Measures against Covid-19 Impact
Table 16. Proposal for HER-2 Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact
Table 17. Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 18. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Regions (US$ Million): 2020 VS 2026
Table 19. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Regions (2015-2020) (US$ Million)
Table 20. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Regions (2015-2020)
Table 21. Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 22. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Regions (2021-2026)
Table 23. Market Top Trends
Table 24. Key Drivers: Impact Analysis
Table 25. Key Challenges
Table 26. HER-2 Targeted Drugs for Breast Cancer Market Growth Strategy
Table 27. Main Points Interviewed from Key HER-2 Targeted Drugs for Breast Cancer Players
Table 28. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Players (2015-2020) (Million US$)
Table 29. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Players (2015-2020)
Table 30. Global Top HER-2 Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2019)
Table 31. Global HER-2 Targeted Drugs for Breast Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table 32. Key Players Headquarters and Area Served
Table 33. Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service
Table 34. Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 37. Global HER-2 Targeted Drugs for Breast Cancer Market Size Share by Type (2015-2020)
Table 38. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type (2021-2026)
Table 39. Global HER-2 Targeted Drugs for Breast Cancer Market Size Share by Application (2015-2020)
Table 40. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 41. Global HER-2 Targeted Drugs for Breast Cancer Market Size Share by Application (2021-2026)
Table 42. North America Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 43. North America Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 44. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 45. North America HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 46. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 47. North America HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 48. Europe Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 49. Europe Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 50. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 51. Europe HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 52. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 53. Europe HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 54. China Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 55. China Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 56. China HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 57. China HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 58. China HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 59. China HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 60. Japan Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 61. Japan Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 62. Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 63. Japan HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 64. Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 65. Japan HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 66. Southeast Asia Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 67. Southeast Asia Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 68. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 69. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 70. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 71. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 72. India Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 73. India Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 74. India HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 75. India HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 76. India HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 77. India HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 78. Central & South America Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 79. Central & South America Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 80. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 81. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 82. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 83. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 84. Roche Company Details
Table 85. Roche Business Overview
Table 86. Roche Product
Table 87. Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 88. Roche Recent Development
Table 89. Chugai Pharmaceutical Company Details
Table 90. Chugai Pharmaceutical Business Overview
Table 91. Chugai Pharmaceutical Product
Table 92. Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 93. Chugai Pharmaceutical Recent Development
Table 94. GlaxoSmithKline Company Details
Table 95. GlaxoSmithKline Business Overview
Table 96. GlaxoSmithKline Product
Table 97. GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 98. GlaxoSmithKline Recent Development
Table 99. Novartis Company Details
Table 100. Novartis Business Overview
Table 101. Novartis Product
Table 102. Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 103. Novartis Recent Development
Table 104. Pfizer Company Details
Table 105. Pfizer Business Overview
Table 106. Pfizer Product
Table 107. Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 108. Pfizer Recent Development
Table 109. CANbridge Company Details
Table 110. CANbridge Business Overview
Table 111. CANbridge Product
Table 112. CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 113. CANbridge Recent Development
Table 114. Puma Biotechnology Company Details
Table 115. Puma Biotechnology Business Overview
Table 116. Puma Biotechnology Product
Table 117. Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 118. Puma Biotechnology Recent Development
Table 119. Hengrui Medicine Business Overview
Table 120. Hengrui Medicine Product
Table 121. Hengrui Medicine Company Details
Table 122. Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 123. Hengrui Medicine Recent Development
Table 124. Beacon Pharmaceuticals Limited Company Details
Table 125. Beacon Pharmaceuticals Limited Business Overview
Table 126. Beacon Pharmaceuticals Limited Product
Table 127. Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 128. Beacon Pharmaceuticals Limited Recent Development
Table 129. Hetero Drugs Company Details
Table 130. Hetero Drugs Business Overview
Table 131. Hetero Drugs Product
Table 132. Hetero Drugs Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 133. Hetero Drugs Recent Development
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
Table 1. HER-2 Targeted Drugs for Breast Cancer Key Market Segments
Table 2. Key Players Covered: Ranking by HER-2 Targeted Drugs for Breast Cancer Revenue
Table 3. Ranking of Global Top HER-2 Targeted Drugs for Breast Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Trastuzumab
Table 6. Key Players of Pertuzumab
Table 7. Key Players of Lapatinib
Table 8. Key Players of Neratinib
Table 9. Key Players of Trastuzumab Emtansine
Table 10. Key Players of Pyrotinib
Table 11. Key Players of Other
Table 12. COVID-19 Impact Global Market: (Four HER-2 Targeted Drugs for Breast Cancer Market Size Forecast Scenarios)
Table 13. Opportunities and Trends for HER-2 Targeted Drugs for Breast Cancer Players in the COVID-19 Landscape
Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 15. Key Regions/Countries Measures against Covid-19 Impact
Table 16. Proposal for HER-2 Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact
Table 17. Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 18. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Regions (US$ Million): 2020 VS 2026
Table 19. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Regions (2015-2020) (US$ Million)
Table 20. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Regions (2015-2020)
Table 21. Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 22. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Regions (2021-2026)
Table 23. Market Top Trends
Table 24. Key Drivers: Impact Analysis
Table 25. Key Challenges
Table 26. HER-2 Targeted Drugs for Breast Cancer Market Growth Strategy
Table 27. Main Points Interviewed from Key HER-2 Targeted Drugs for Breast Cancer Players
Table 28. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Players (2015-2020) (Million US$)
Table 29. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Players (2015-2020)
Table 30. Global Top HER-2 Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2019)
Table 31. Global HER-2 Targeted Drugs for Breast Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table 32. Key Players Headquarters and Area Served
Table 33. Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service
Table 34. Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 37. Global HER-2 Targeted Drugs for Breast Cancer Market Size Share by Type (2015-2020)
Table 38. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type (2021-2026)
Table 39. Global HER-2 Targeted Drugs for Breast Cancer Market Size Share by Application (2015-2020)
Table 40. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 41. Global HER-2 Targeted Drugs for Breast Cancer Market Size Share by Application (2021-2026)
Table 42. North America Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 43. North America Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 44. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 45. North America HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 46. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 47. North America HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 48. Europe Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 49. Europe Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 50. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 51. Europe HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 52. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 53. Europe HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 54. China Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 55. China Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 56. China HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 57. China HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 58. China HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 59. China HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 60. Japan Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 61. Japan Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 62. Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 63. Japan HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 64. Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 65. Japan HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 66. Southeast Asia Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 67. Southeast Asia Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 68. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 69. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 70. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 71. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 72. India Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 73. India Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 74. India HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 75. India HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 76. India HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 77. India HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 78. Central & South America Key Players HER-2 Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$)
Table 79. Central & South America Key Players HER-2 Targeted Drugs for Breast Cancer Market Share (2019-2020)
Table 80. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 81. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)
Table 82. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 83. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)
Table 84. Roche Company Details
Table 85. Roche Business Overview
Table 86. Roche Product
Table 87. Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 88. Roche Recent Development
Table 89. Chugai Pharmaceutical Company Details
Table 90. Chugai Pharmaceutical Business Overview
Table 91. Chugai Pharmaceutical Product
Table 92. Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 93. Chugai Pharmaceutical Recent Development
Table 94. GlaxoSmithKline Company Details
Table 95. GlaxoSmithKline Business Overview
Table 96. GlaxoSmithKline Product
Table 97. GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 98. GlaxoSmithKline Recent Development
Table 99. Novartis Company Details
Table 100. Novartis Business Overview
Table 101. Novartis Product
Table 102. Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 103. Novartis Recent Development
Table 104. Pfizer Company Details
Table 105. Pfizer Business Overview
Table 106. Pfizer Product
Table 107. Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 108. Pfizer Recent Development
Table 109. CANbridge Company Details
Table 110. CANbridge Business Overview
Table 111. CANbridge Product
Table 112. CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 113. CANbridge Recent Development
Table 114. Puma Biotechnology Company Details
Table 115. Puma Biotechnology Business Overview
Table 116. Puma Biotechnology Product
Table 117. Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 118. Puma Biotechnology Recent Development
Table 119. Hengrui Medicine Business Overview
Table 120. Hengrui Medicine Product
Table 121. Hengrui Medicine Company Details
Table 122. Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 123. Hengrui Medicine Recent Development
Table 124. Beacon Pharmaceuticals Limited Company Details
Table 125. Beacon Pharmaceuticals Limited Business Overview
Table 126. Beacon Pharmaceuticals Limited Product
Table 127. Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 128. Beacon Pharmaceuticals Limited Recent Development
Table 129. Hetero Drugs Company Details
Table 130. Hetero Drugs Business Overview
Table 131. Hetero Drugs Product
Table 132. Hetero Drugs Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$)
Table 133. Hetero Drugs Recent Development
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Type: 2020 VS 2026
Figure 2. Trastuzumab Features
Figure 3. Pertuzumab Features
Figure 4. Lapatinib Features
Figure 5. Neratinib Features
Figure 6. Trastuzumab Emtansine Features
Figure 7. Pyrotinib Features
Figure 8. Other Features
Figure 9. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026
Figure 10. Hospital Case Studies
Figure 11. Clinic Case Studies
Figure 12. Drug Center Case Studies
Figure 13. Other Case Studies
Figure 14. HER-2 Targeted Drugs for Breast Cancer Report Years Considered
Figure 15. Global HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Regions: 2020 VS 2026
Figure 17. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Players in 2019
Figure 20. Global Top HER-2 Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2019
Figure 21. The Top 10 and 5 Players Market Share by HER-2 Targeted Drugs for Breast Cancer Revenue in 2019
Figure 22. North America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Roche Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 31. Chugai Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Chugai Pharmaceutical Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 33. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. GlaxoSmithKline Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 35. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Novartis Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 37. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Pfizer Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 39. CANbridge Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. CANbridge Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 41. Puma Biotechnology Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Puma Biotechnology Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 43. Hengrui Medicine Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Hengrui Medicine Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 45. Beacon Pharmaceuticals Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Beacon Pharmaceuticals Limited Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 47. Hetero Drugs Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Hetero Drugs Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed
Figure 1. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Type: 2020 VS 2026
Figure 2. Trastuzumab Features
Figure 3. Pertuzumab Features
Figure 4. Lapatinib Features
Figure 5. Neratinib Features
Figure 6. Trastuzumab Emtansine Features
Figure 7. Pyrotinib Features
Figure 8. Other Features
Figure 9. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026
Figure 10. Hospital Case Studies
Figure 11. Clinic Case Studies
Figure 12. Drug Center Case Studies
Figure 13. Other Case Studies
Figure 14. HER-2 Targeted Drugs for Breast Cancer Report Years Considered
Figure 15. Global HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Regions: 2020 VS 2026
Figure 17. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Players in 2019
Figure 20. Global Top HER-2 Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2019
Figure 21. The Top 10 and 5 Players Market Share by HER-2 Targeted Drugs for Breast Cancer Revenue in 2019
Figure 22. North America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Roche Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 31. Chugai Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Chugai Pharmaceutical Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 33. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. GlaxoSmithKline Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 35. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Novartis Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 37. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Pfizer Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 39. CANbridge Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. CANbridge Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 41. Puma Biotechnology Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Puma Biotechnology Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 43. Hengrui Medicine Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Hengrui Medicine Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 45. Beacon Pharmaceuticals Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Beacon Pharmaceuticals Limited Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 47. Hetero Drugs Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Hetero Drugs Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed